Tour de France Champions born or made: where do we take the genetics of performance? by Moran, Colin Neil & Pitsiladis, Yannis
Tour de France Champions born or made: where do we take the 
genetics of performance? 
 
Colin N. Moran1* and Yannis P. Pitsiladis2 
 
1Physiology Exercise and Nutrition Research Group, University of Stirling, Stirling, Scotland. 
Email: colin.moran@stir.ac.uk, Tel: +44 (0) 1786 466510. 
2FIMS Reference Collaborating Centre of Sports Medicine for Anti-Doping Research, 
University of Brighton,  Eastbourne, England. Email: y.pitsiladis@brighton.ac.uk, Tel: +44 (0) 
1273 643707. 
 
 *Corresponding author 
 
 
Running title: The future of cycling and performance genetics 
Word count: 3433 
Acknowledgements: 
The authors have no conflicts of interest to declare. The authors are supported by grants 
from the World Antidoping Agency, the Diabetes Research and Wellness Foundation, the 
Novo Nordisk Foundation, the Royal Society and Tenovus Scotland. 
  
Abstract (200 words) 
Cyclists in the Tour de France are endurance specialists. Twin and family studies have shown 
that approximately 50% of the variance in a number of performance related phenotypes 
(whether measured at baseline, i.e. natural talent, or in response to training) including those 
important to cycling can be explained by genetic variation. Research into the specific genetic 
variants that are responsible has identified over 200 genes containing common genetic 
variants involved in the genetic predisposition to physical performance. However, typically 
these explain only a small portion of the variance, perhaps 1-2% and collectively they rarely 
explain anything approaching the 50% of the variance identified in the twin and family 
studies. Thus, there is a gap in our understanding of the relationship between heritability 
and performance. This gap may be bridged by investigation of rare variants or epigenetic 
variation or by altering study designs through increased collaborations to pool exiting 
cohorts together. Initial findings from such efforts show promising results. This mini-review 
will touch on the genetics and epigenetics of sporting performance, how they relate to 
cyclists in the Tour de France and where best future efforts may be directed as well as discuss 
some preliminary research findings. 
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Introduction 
Since at least the time of the Ancient Greeks humans have challenged each other in 
competitive performance tasks. Concomitantly scholars have attempted to identify the 
determinants of performance and thus methods to improve performance. Aristotle, in his 
Nicomachean Ethics (Aristotle, 2002), wrote, “both excessive and insufficient exercise 
destroy one's strength, and both eating and drinking too much or too little destroy health, 
whereas the right quantity produces, increases or preserves it.” Modern day sports science 
maintains these efforts and is in part responsible for the continued improvements in 
performance in most sports that we see to the present day. In cycling we have seen 
improvements in the technology of the bicycle, the athlete’s diet, nutritional strategies 
during the race and in types and management of training to name only a few of the areas of 
advancement. Competitors in the Tour de France are supported by a large team of experts 
including Sport Scientists, Physiotherapists, Medics and Nutritionists. However, given the 
right team, resources and training, the question remains whether anyone can win the Tour 
de France or whether champions are born with some innate genetic advantage over others.  
The Tour de France is a gruelling endurance event. The cyclists who take part are endurance 
experts. Typically the race covers 3200-4000 km and contains long flat stages, shorter 
individual time trials and uphill stages. Although the cyclists may specialise, or be more suited 
to, one type of terrain, they have to cover all three types of terrain. Their characteristics are 
reviewed in Lucia, Hoyos, & Chicharro (2001). In summary, typically they will all have high 
maximal power output (>500 W) in incremental tests with 1 minute increments, high power 
to weight ratio (6-7.5 W/kg), high maximal oxygen uptake (?̇?𝑂2𝑚𝑎𝑥; 70-80 ml/min/kg) and a 
high anaerobic threshold (~90% ?̇?𝑂2𝑚𝑎𝑥) although the precise values vary depending on 
their specialism. Physiologically, they are likely to have low body fat (8-10%), large hearts 
(152 g/m2 mean ventricular mass index), large arteries (~13% larger carotid arteries), higher 
skeletal muscle type I fibre content (Coyle et al., 1991) and increased mitochondrial volume 
(Rodríguez et al., 2002). Whilst many of these characteristics may be altered by training 
(Rivera-Brown & Frontera, 2012) several have also been shown to be influenced by genetics 
(see Wolfarth et al., 2014 for review). Thus, rather than ask whether Tour de France 
champions are born or made it is more appropriate to ask what the extent is of the influence 
of genetics on the making of Tour de France champions. 
Genetic Variation, Heritability and Performance 
The Human Genome Project was completed over a decade ago (Lander et al., 2001). 
However, we all carry slightly different versions of that DNA sequence and in terms of 
understanding human physiology the sequence differences between us are as interesting as 
the basic sequence itself. Subsequent projects such as the HapMap (International HapMap 
Consortium, 2005) and 1000genomes (Abecasis et al., 2012) projects have provided 
information on the extent of the variation between individuals. Ultimately, it is clear that 
whilst human DNA sequences are highly similar (~99%) there are a large number of sites in 
our DNA at which we vary (~38 million); and, that the rate of variation at these sites has a 
wide range with some variants very common in the population and others very rare. For 
example, the minor allele of alpha-actinin-3 variant rs1815739 has a global frequency of 40% 
whilst the minor allele of the erythropoietin receptor variant rs121917830 has a global 
frequency of <0.001%. 
To understand how these genetic variants relate to cycling performance or to sports 
performance in general we also need to assess human performance variation and relate that 
to the genetic differences. However, few studies specifically investigate cyclists. In a general 
sense, it is widely recognised that humans display a large variation in physical performance 
(e.g. Bouchard et al., 1998). We also think of some individuals as naturally talented and 
others as lacking in talent (Hyllegard, Radlo, & Early, 2001; Williams & Reilly, 2000). Similarly, 
we see some individuals make large gains in performance with training whilst others show 
little or no response to training (Bouchard et al., 1999). Furthermore, individuals often excel 
at endurance based sports or power based sports, but rarely both. In part these differences 
will result from differing training modalities (i.e. more sprint / power or endurance) and 
opportunities for sports participation. However, talented individuals often come from 
talented families (De Moor et al., 2007) and whilst families share many aspects of their 
environments, they also share known amounts of their DNA depending on the relationship 
between the specific individuals in question. If genetic variation is even partially responsible 
for the physiological characteristics important for cycling, then unique combinations of 
variants are likely to have the potential to predispose an individual towards elite cycling 
ability. 
Twin and family studies make use of the known quantity of shared DNA to partition the 
variance in performance that can be explained by environmental factors or by genetic 
factors. A British twin study, which included a small number of cyclists, found that athlete 
status runs in families and has a large genetic component (De Moor et al., 2007). If we focus 
on endurance capacity, a key aspect of cycling performance, the classic family study is the 
HERITAGE study (Bouchard et al., 1998, 1999). Bouchard and colleagues recruited 98 families 
comprised of 481 sedentary individuals to a training study. They measured their maximum 
aerobic capacity (?̇?𝑂2𝑚𝑎𝑥), then trained these individuals 3 times a week for 20 weeks before 
measuring their ?̇?𝑂2𝑚𝑎𝑥 again. The average gain in ?̇?𝑂2𝑚𝑎𝑥 was approximately 0.4 L/min 
although there was a very large range of values from little or no gain to gains over 1 L/min.  
Due to the relatedness of the family members they were able to estimate that approximately 
50% of the variance in ?̇?𝑂2𝑚𝑎𝑥 could be explained by genetic variation (whether measured 
at baseline, i.e. natural talent, or in response to training). This implies that genetic variation 
is at least as important to performance as everything else put together, i.e. lifestyle, diet, 
training, facilities, etc. 
Common Genetic Variants 
Research into the specific genetic variants that are responsible for this genetic portion of the 
variance has identified over 200 genes containing common genetic variants involved in the 
genetic predisposition to aspects of physical performance (Wolfarth et al., 2014). Work on 
the genetics of sporting performance has involved cohorts of elite level athletes from around 
the globe and from a variety of sports. It includes Ethiopian and Kenyan endurance runners, 
track sprinters from Jamaica and the USA and both endurance runners and sprinters from 
Australia, Russia, and Japan. However, although several of these cohorts include endurance 
cyclists, typically the number of cyclists is small and very little research has been done directly 
on the genetics of cycling performance. Contrast the number of performance related genes 
(>200) with the less than 20 genes that have been investigated in cohorts containing cyclists 
(Table 1). Cyclists are often included because many of the characteristics important to cycling 
performance, such as high ?̇?𝑂2𝑚𝑎𝑥 or high anaerobic threshold, are common to other 
endurance sports. Thus, they are included as part of an endurance sports group with little 
more detailed information. Furthermore, it is rare for these cohorts to include quantitative 
measurements of all the key performance characteristics known to be important to cycling 
performance. Obtaining quantitative measurements requires more of the athletes’ time and 
thus makes recruitment more challenging. Consequently, most of what is known about the 
genetics of cycling performance is inferred from other sports requiring similar physiological 
traits. More, larger studies including elite cyclists are warranted. 
Perhaps the best known example of a performance variant is alpha-actinin-3 (ACTN3) R577X 
(rs1815739) which has been strongly linked to sprinting ability (Moran et al., 2007; Yang et 
al., 2003) and less conclusively with endurance ability (Alfred et al., 2011).  ACTN3 is a muscle 
structural protein mostly found in type 2 fibres. It is an unusual variant in that the X-allele is 
a nonsense allele and XX homozygotes carry no functional ACTN3 whatsoever despite being 
relatively common (approximately 16% of the global population, ranging from approximately 
1 to 30% in various populations). These individuals survive due to functional redundancy 
between ACTN3 and alpha-actinin-2 (ACTN2) although that redundancy must be incomplete 
since XX homozygotes are significantly less likely to become elite sprinters. This and similar 
findings have been replicated in many cohorts (Berman & North, 2010). Although a small 
number of studies find no association with sprint / power performance (e.g. Rodríguez-Romo 
et al., 2013), it is likely that this can be explained by statistical chance or subject differences. 
Conversely, the X-allele has been linked to endurance capacity (Yang et al., 2003) although 
somewhat less conclusively (Alfred et al., 2011). Three studies (Table 1) have investigated 
the association between ACTN3 genotype and endurance cycling hypothesising that they 
would find an over-representation of the X-allele in elite cyclists. However, two studies found 
no association and the third found an under-representation of the X-allele in cyclists. 
Typically, these common genetic variants, including ACTN3 R577X, explain only a small 
portion of the phenotypic variance, perhaps 1-2%. Such small effects are difficult to identify 
without very large cohorts. This is compounded by the fact that case-control approaches 
assume that the controls have little or no genetic predisposition towards athleticism; 
however, it is much more likely that they contain a number of genetically predisposed 
individuals who are simply inactive and therefore not meeting their athletic potential (Tucker 
& Collins, 2012). Furthermore, predisposing variants are often identified in small cohorts 
without replication of the findings in secondary cohorts (see Pitsiladis et al., 2013 for review). 
Thus there is a risk that many of the variants identified so far may be false positive artefacts 
of small cohorts with only the most robustly replicated variants, such as ACTN3 R577X, being 
true positives. In part, this problem is due to the difficulty in recruiting large enough numbers 
of elite athletes who are a very small minority of any population. Furthermore, collectively 
the genetic variants rarely explain anything approaching the 50% of the variance identified 
in the twin and family studies. Thus, a gap in our understanding of the relationship between 
heritability and performance exists. 
Rare Genetic Variants 
One possible explanation for this gap in understanding is that we have yet to fully consider 
the influence of rare genetic variants on sports performance. Until recently, studies into the 
genetics of quantitative traits concentrated on common genetic variants; that is variants with 
a minor allele frequency in the population of > 1%. The rationale for this was partly based on 
the common variant common disease hypothesis (Lander, 1996) which postulates that 
quantitative phenotypes with a classic bell-shaped distribution are the result of the influence 
of many 10s-100s of genes, each with a small influence on phenotype. However, there were 
also practical and commercial reasons. Practically, studies into rare variants needed very 
large cohorts of unrelated individuals to identify enough rare homozygotes to study. Also, 
due to their rarity, not all rare variants have necessarily been identified by current DNA 
sequencing efforts, even now. Commercially, biotechnology companies generally produce 
technologies that can be sold to mass markets to maximise their profits thus the focus 
remained on common variants. However, with the ever decreasing cost and increasing speed 
of next generation DNA sequencing (NGS) (Wetterstrand, 2014) it is now feasible to perform 
whole genome DNA sequencing on large cohorts of individuals thus identifying unknown rare 
variants and allowing testing of their associations with quantitative phenotypes. 
Rare variants are already known to influence performance; although the best example was 
not identified by modern NGS but instead by the more traditional and slower genetic method 
of identifying a disease-carrying family and following the disease through the generations of 
that family. Nonetheless this example highlights the potential of the infinitely higher 
throughput method of NGS to identify additional rare variants with significant influences. 
Eero Mäntyranta was a Finnish cross county skier in the 1960s. Cross country skiers are also 
endurance experts sharing many physiological characteristics with cyclists. Eero Mäntyranta 
collected 7 Olympic medals, 5 World Championship medals and 9 domestic championship 
medals making him a truly World class athlete (Olympic.org, 2014). Several members of his 
extended family suffered from a disease called familial erythrocytosis-1 (ECYT-1) due to a 
rare variant (rs121917830) of their erythropoietin receptors (de la Chapelle, Träskelin, & 
Juvonen, 1993). Collectively the related diseases of ECYT1-4 occur at a frequency of less than 
1 in 100,000 (Hussein, Percy, & McMullin, 2012) so rs121917830 is a rare variant by any 
standard although precise allele frequency information on rs121917830 is not available. 
Normally, erythropoietin (EPO) is produced in response to low oxygen levels. It activates the 
EPO receptor (EPOR) resulting in the production of more red blood cells and thus an increase 
in the oxygen carrying capacity of the blood. Individuals with ECYT-1 have variant EPORs that 
are effectively hypersensitive to EPO; thus they have an increased red blood cell count and 
the oxygen carrying capacity of their blood can be increased by up to 50%. The extra blood 
cells thicken their blood putting them at risk of abnormal blood clots which can cause life 
threatening complications; however, if they exercise, the additional oxygen carrying capacity 
gives them an advantage at endurance events; similar to the effects of injecting the drug EPO 
(Durussel et al., 2013). It is this kind of natural variation that creates the necessity for a 
complex biological passport rather than a simple permissible threshold. Such a variant would 
also likely be of benefit to individuals involved in elite cycling. Paradoxically, those carrying 
rs121917830 variation are likely to derive less, if any, benefit from the illicit use of EPO. 
Rare variants are expected to have larger influences on phenotype than common variants in 
part explaining why they remain rare since larger influences on phenotype are likely to be 
less well tolerated. So far, rare variant studies have concentrated on major human diseases 
such as cancer (Stadler, Schrader, Vijai, Robson, & Offit, 2014) or cardiovascular disease 
(Peloso et al., 2014). However, typically these rare variants have been in the same genes as 
the established common variants and have not furthered our understanding of these 
phenotypes as much as was anticipated. It seems likely that when NGS is applied to elite 
cyclists or performance phenotypes that some rare variants with important influences will 
be identified although it seems equally unlikely that this will be the whole story. 
Epigenetic Variation 
Another source of heritable variation that may help explain the gap in our understanding is 
through epigenetic coding. Physiological epigenetics is a rapidly developing field with great 
promise. Epigenetics includes histone modifications, DNA methylation and RNA interference 
by non-coding RNAs such as microRNA (miRNA). This review will only cover miRNAs although 
both histone modifications and DNA methylation are involved in control of gene expression 
and are also likely important to sports performance (Ling & Rönn, 2014; McGee, Fairlie, 
Garnham, & Hargreaves, 2009). Like genetic variants, epigenetic modifications are heritable 
(Rissman & Adli, 2014); however, unlike genetic variants, they are also malleable within an 
individual (Baggish et al., 2011; Barrès et al., 2012). Thus, understanding epigenetic 
modifications may not only help us understand which individuals have the most sporting 
potential but also help understand how they can be manipulated through appropriate 
training and dietary regimes that may help improve performance. 
The traditional view of molecular biology, encapsulated in the central dogma (Crick, 1970) 
held that proteins were easily the most important functional molecule in a cell and that RNA 
was mostly an intermediate step between DNA and proteins (excepting tRNA and rRNA). 
However, recent data from the ENCODE project (Bernstein et al., 2012) suggests that whilst 
approximately 75% of the genome is transcribed into RNA (Djebali et al., 2012) only a small 
proportion of that (1-3%) is directly involved in protein coding (Bernstein et al., 2012). Thus 
the vast majority of RNA is non-protein-coding. However, much of this non-protein-coding 
RNA appears to have functions which are only now beginning to be explored. A number of 
recent studies in exercise genomics have recognised the importance of non-coding RNAs, 
specifically miRNAs (Kirby & McCarthy, 2013). miRNAs are involved in post-transcriptional 
control of messenger RNA (mRNA) either by inhibiting their translation, or by targeting 
mRNAs for degradation (Guay, Roggli, Nesca, Jacovetti, & Regazzi, 2011). Each miRNA can 
bind multiple mRNAs and each mRNA can be bound by multiple miRNAs; therefore, miRNAs 
comprise a highly complex network of regulators that fine tune gene and protein expression. 
miRNAs have been shown to be involved in muscle cell development (Luo, Nie, & Zhang, 
2013), respond to exercise both acutely and chronically (Russell et al., 2013) and be 
predictive of response to training (Davidsen et al., 2011). Intriguingly, miRNAs also have been 
found at stable levels in plasma (Chen et al., 2008; Mitchell et al., 2008). Plasma miRNAs have 
been shown to both respond to exercise (Baggish et al., 2011; Davidsen et al., 2011) and be 
dysregulated in disease (Chen et al., 2008; Mitchell et al., 2008). There also is growing 
evidence that plasma miRNAs are taken up by target tissues and may be involved in cell-cell 
communication (Rayner & Hennessy, 2013). By nature of their location in the circulation, 
plasma miRNAs have the potential to fine tune the gene expression and protein translation 
of multiple genes in multiple tissues and thus may have influence in coordinating the whole 
body response to exercise such as cycling. miRNAs, mRNA and proteins comprise a very 
complex system regulating the function of cells. This type of complexity can only be captured 
in systems biology models and future research should endeavour to create such models for 
exercise phenotypes to build a complete understanding of the determinants of cycling 
performance and sports performance in general. 
Elite Athlete Cohorts 
A final source of the gap in our understanding of the heritability of cycling and exercise 
performance may be due to the specific cohorts and phenotypes within those cohorts that 
have so far been used. Collecting large cohorts is time-consuming and elite athletes are rare; 
elite cyclists even rarer. Thus, collecting large enough numbers of them for comprehensive 
studies is difficult. Furthermore, quantitative measurements allow the use of more powerful 
statistical techniques. However, elite athletes have strict training regimes and are generally 
unwilling to come to the laboratory for detailed physiological testing, training interventions 
or invasive procedures that may impede their training in the ensuing days. A partial answer 
to this may be to pool our efforts by combining existing cohorts of athletes for genome wide 
association studies (GWAS) or NGS studies with subsequent replication in existing secondary 
cohorts. Initial findings from such efforts show promising results. With this objective in mind, 
two consortia have recently been formed to conduct the first GWAS of elite athletic 
performance using existing athlete cohorts, summarised in Table 2 (and described in 
Pitsiladis et al., 2013): the PowerGene consortium and GAMES Consortium (Genomic 
Variants Associated with Elite Endurance Athlete Status). Preliminary findings show 
promising odds ratios and a trend towards the conventional GWAS significance threshold at 
p ≤ 5 x 10-8. Further validation of these signals in independent cohorts will be required, and 
any replicated SNPs taken forward for fine-mapping / targeted re-sequencing and functional 
studies to uncover the underlying biological mechanisms. Both of these consortia are now 
part of the much larger Athlome Consortium (http://www.athlomeconsortium.org/) which 
will facilitate replication and further analyses of their signals as well as foster new 
discoveries. 
Conclusions 
To move performance genetics and in particular cycling performance genetics forward we 
need: (1) to collect larger cohorts of elite athletes and in particular cyclists as well as 
persuade them of the importance of collecting detailed phenotypic information; (2) to 
collaborate to pool existing cohorts together; (3) when possible collect additional samples 
such as blood, plasma and tissue that will allow future epigenetic analyses; (4) to pursue 
cutting edge technologies such as next generation sequencing, transcriptomics and 
proteomics; and (5) to integrate all these results into systems biology models. 
Finally, can anyone become champion of the Tour de France? For this to happen an individual 
must possess the right genetic and epigenetic variation to display natural talent at cycling, 
the right genetic and epigenetic variation to be able to respond to appropriate training and 
do the training with the right team supporting them in the right way. This is not an either / 
or situation. Champions of the Tour de France are both born and made: genetic and 
epigenetic variations provide the potential in some individuals but they must then unlock 
that potential with appropriate training and lifestyle. 
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Table(s) with caption(s) (on individual pages) 
GENE VARIANT STUDY DESIGN ATHLETES ETHNICITY 
& GENDER 
ATHLETES 
(CYCLISTS) 
CONTROLS ASSOCIATION (REFERENCE) 
ACE rs4646994 
(intron 16 
indel) 
Case-control Professional cyclists, long-
distance runners and handball 
players 
Spanish 
males 
60 (25) 400 I-allele over-represented in athletes compared 
to controls (Alvarez et al., 2000). 
  Case-control Professional cyclists and 
Olympic-class endurance 
runners 
Spanish 
males 
77 (50) 119 DD genotype over-represented in cyclists 
compared to controls or runners. D-allele over-
represented in cyclists compared to runners 
(Lucía et al., 2005). 
  Case-control Mixed endurance and power or 
sprint sports 
Iranian 
males 
156 (37) 163 D-allele over-represented in cyclists compared 
to controls (Shahmoradi, Ahmadalipour, & 
Salehi, 2014). 
  Case-control Professional cyclists, Olympic-
class endurance runners and 
World class rowers 
Spanish 
males 
141 (50) 123 II under-represented in rowers compared to 
whole cohort (Muniesa et al., 2010). 
  Case-control  
Quantitative 
muscle power 
Endurance, power and mixed 
athletes 
Lithuanian 
males and 
females 
193 (12) 250 DD genotype over-represented in endurance 
compared to power athletes. DD genotype 
lower power than II genotype (Ginevičienė, 
Pranckevičienė, Milašius, & Kučinskas, 2010). 
ACTN3 rs1815739 
(p.R577X) 
Case-control 
Quantitative 
?̇?𝑂2𝑚𝑎𝑥 data 
Professional cyclists and 
Olympic-class endurance 
runners 
Spanish 
males 
102 (50) 123 No association with endurance (Lucia et al., 
2006). 
  Case-control Endurance-oriented athletes 
including road cyclists 
Russian 
males and 
females 
456 (34) 1211 C-allele (577X) under-represented in endurance 
athletes (Ahmetov, Druzhevskaya, et al., 2010). 
  Case-control Professional cyclists, Olympic-
class endurance runners and 
World class rowers 
Spanish 
males 
141 (50) 123 No association with endurance (Muniesa et al., 
2010). 
  Case-control  
Quantitative 
muscle power 
Endurance, power and mixed 
athletes 
Lithuanian 
males and 
females 
193 (12) 250 No association with athlete group or power 
(Ginevičienė, Pranckevičienė, Milašius, & 
Kučinskas, 2010). 
ADRB3 rs4994 
(p.W64R) 
Case-control Professional cyclists, Olympic-
class endurance runners and 
power athletes 
Spanish 
males 
153 (50) 100 C-allele (64R) over-represented in endurance 
athletes compared to controls (Santiago et al., 
2011). 
AGT rs699 
(p.M235T) 
Case-control Professional cyclists, Olympic-
class endurance runners and 
power athletes 
Spanish 
males 
163 (50) 119 No association with endurance. C-allele (235T) 
may favour power performance (Gomez-
Gallego et al., 2009). 
  Case-control Professional cyclists, long-
distance runners and handball 
players  
Spanish 
males 
60 (25) 400 No association with endurance (Alvarez et al., 
2000). 
AGTR1 rs12721277 
(c.*82G>A) 
Case-control Professional cyclists, long-
distance runners and handball 
players  
Spanish 
males 
60 (25) 400 No association with endurance (Alvarez et al., 
2000). 
AMPD1 rs17602729 
(p.Q45X) 
Case-control 
Quantitative 
?̇?𝑂2𝑚𝑎𝑥 data 
Professional cyclists and 
Olympic-class endurance 
runners 
Spanish 
males 
104 (50) 100 C-allele (45Q) over-represented in endurance 
athletes although do not have higher ?̇?𝑂2𝑚𝑎𝑥 
(Rubio et al., 2005). 
  Case-control Professional cyclists, Olympic-
class endurance runners and 
World class rowers 
Spanish 
males 
141 (50) 123 No association with endurance (Muniesa et al., 
2010). 
  Case-control  
Quantitative 
muscle power 
Endurance, power and mixed 
athletes 
Lithuanian 
males and 
females 
204 (12) 260 TT genotype (45XX) absent from athlete group. 
T-allele under-represented in power athletes 
compared to controls. CC genotype associated 
with muscle power (Ginevičienė et al., 2014). 
CKMM rs8111989 
(g.45809208
T>C) 
Case-control Professional cyclists and 
Olympic-class endurance 
runners 
Spanish 
males 
77 (50) 119 No association with endurance (Lucía et al., 
2005). 
  Case-control Professional cyclists, Olympic-
class endurance runners and 
World class rowers 
Spanish 
males 
141 (50) 123 No association with endurance (Muniesa et al., 
2010). 
GDF8 rs1805086 
(p.K153R) 
Case-control Professional cyclists, Olympic-
class endurance runners and 
World class rowers 
Spanish 
males 
141 (50) 123 No association with endurance (Muniesa et al., 
2010). 
HFE rs1799945 
(p.H63D) 
Case-control Professional road cyclists with 
hyperferritinemia 
French 
males 
77 (77) 254 G-allele (63D) over-represented in cyclists 
compared to controls (Deugnier et al., 2002). 
  Case-control 
Quantitative 
?̇?𝑂2𝑚𝑎𝑥 data 
Professional cyclists and 
Olympic-class endurance 
runners 
Spanish 
males 
65 (50) 
 
134 G-allele (63D) over-represented in endurance 
athletes although do not have higher ?̇?𝑂2𝑚𝑎𝑥 
(Chicharro et al., 2004). 
IL6 rs1800795 
(c.-174C>G) 
Case-control Professional cyclists, Olympic-
class endurance runners and 
power athletes 
Spanish 
males 
153 (50) 100 No association with endurance. GG genotype 
and G-allele over-represented in power 
athletes compared to controls or endurance 
athletes (Ruiz et al., 2010). 
IL15RA rs2228059 
(p.N12T) 
Case-control Mixed endurance and sprint-
power sports 
European 
Australian 
males and 
females 
308 (73: 43 
endurance; 
30 sprint-
power) 
258 A-allele (12N) over-represented in all cyclists 
compared to controls (Pistilli et al., 2011). 
MtDNA Haplogroup Case-control Professional cyclists, Olympic-
class endurance runners and 
power athletes 
Spanish 
males 
153 (50) 
 
478 V haplogroup over-represented in elite 
endurance athletes compared to controls 
(Nogales-Gadea et al., 2011). 
NOS3 rs2070744 
(c.-786C>T) 
Case-control Professional cyclists, Olympic-
class endurance runners and 
power athletes 
Spanish 
males 
153 (50) 
 
100 No association with endurance. TT genotype 
and T-allele over-represented in power athletes 
compared to controls or endurance athletes 
(Gómez-Gallego et al., 2009). 
PER3 VNTR (54 bp 
repeat) 
Case-control Cyclists, runners and Ironman 
triathletes 
South 
African 
males of 
European 
descent 
532 (125) 96 PER3(5/5) over-represented in all athletes 
compared to controls (Kunorozva, Stephenson, 
Rae, & Roden, 2012). 
PPARA rs4253778 
(c.2528G>C) 
Case-control  
Quantitative 
muscle power 
Endurance, power and mixed 
athletes 
Lithuanian 
males and 
females 
193 (12) 250 C-allele over-represented in all athletes 
compared to controls (Ginevičienė, 
Pranckevičienė, Milašius, & Kučinskas, 2010). 
PPARD rs2016520 
(c.-87C>T) 
Case-control Endurance and power athletes 
from a range of sports 
Russian 
males and 
females 
1256 (108) 610 C-allele over-represented in endurance athletes 
(Ahmetov, Astratenkova, & Rogozkin, 2007) 
PPARGC1A rs8192678 
(p.G482S) 
Case-control 
Quantitative 
?̇?𝑂2𝑚𝑎𝑥 data 
Professional cyclists and 
Olympic-class endurance 
runners 
Spanish 
males 
104 (50) 164 G-allele (482G) predicts exceptional endurance 
capacity (Lucia et al., 2005). 
  Case-control Professional cyclists, Olympic-
class endurance runners and 
World class rowers 
Spanish 
males 
141 (50) 123 No association with endurance (Muniesa et al., 
2010). 
  Case-control  
Quantitative 
muscle power 
Endurance, power and mixed 
athletes 
Lithuanian 
males and 
females 
193 (12) 250 482S homozygotes had higher power 
performance (Ginevičienė, Pranckevičienė, 
Milašius, & Kučinskas, 2010). 
TFAM rs1937 
(p.S12T) 
Case-control 
Quantitative 
?̇?𝑂2𝑚𝑎𝑥 data 
Endurance and power athletes 
from a range of sports 
Russian 1537 (109) 1113 C-allele (12T) over-represented in endurance 
athletes (Ahmetov, Popov, Missina, 
Vinogradova, & Rogozkin, 2010). 
VEGFA rs2010963 
(c.-634C>G) 
Case-control 
Quantitative 
?̇?𝑂2𝑚𝑎𝑥 data 
Endurance and power athletes 
from a range of sports 
Russian 
males and 
females 
670 (110) 1073 C-allele over-represented in endurance athletes 
(Ahmetov et al., 2008). 
VEGFR2 rs1870377 
(p.Q472H) 
Case-control 
Quantitative 
?̇?𝑂2𝑚𝑎𝑥 data 
Endurance and power athletes 
from a range of sports 
Russian 
males and 
females 
471 (11) 603 A-allele (472Q) with endurance-related 
phenotypes (Ahmetov et al., 2009). 
Table 1. Candidate gene association studies comparing cyclists to controls showing study characteristics and findings. 
STUDY PRIMARY DESIGN PARTICIPANTS 
GENATHLETE Candidate gene case-
control multicentre study 
~300 Endurance athletes with high ?̇?𝑂2𝑚𝑎𝑥 
~300 Untrained controls with low to average ?̇?𝑂2𝑚𝑎𝑥 
RUSSIAN 
COHORT 
Candidate gene case-
control study involving 24 
different athletic 
disciplines 
1423 Russian endurance athletes of regional or national competitive 
standards 
1242 Russian controls 
EAST 
AFRICAN 
COHORT 
Candidate gene case-
control study 
291 Kenyan endurance athletes of national / international standard 
85 Kenyan controls 
76 Ethiopian endurance athletes from junior / senior national athletic 
teams 
315 Ethiopian controls 
JAMAICAN 
AND USA 
COHORT 
Candidate gene case-
control study and GWAS 
116 Jamaican sprint athletes of national/ international competitive 
standard 
311 Jamaican controls 
114 African-American sprint athletes of national / international 
competitive standard 
191 African-American controls 
AUSTRALIAN 
COHORT 
Candidate gene case-
control study involving 14 
different sports 
429 Elite white athletes 
436 White controls 
JAPANESE 
COHORT 
Candidate gene case-
control study and GWAS 
717 Japanese athletes of national / international competitive standard 
including 381 track and field athletes, 166 swimmers and 170 
Olympians from various sports 
814 Japanese controls 
EUROPEAN 
AND ASIAN 
SWIMMING 
COHORT 
Candidate gene case-
control study 
200 Caucasian swimmers of world-class status 
158 Japanese of national competitive standards 
649 Japanese controls 
168 Taiwanese swimmers of national / international competitive 
standards 
603 Taiwanese controls 
SPANISH 
COHORT 
Candidate gene case-
control study 
100 Spanish male endurance athletes of world-class status 
54 Spanish male rowers of world-class status 
108 All-time best Spanish Judo male athletes 
88 Swimmers of national level 
53 Power athletes of national / international competitive standards 
343 Spanish controls 
ISRAELI 
COHORT 
Candidate gene case-
control study 
74 Israeli endurance athletes of national / international competitive 
standard 
81 Power athletes of national / international competitive standard 
240 Israeli controls 
CHINESE 
COHORT 
Candidate gene case-
control study 
241 Chinese (HAN) endurance athletes 
504 Chinese (HAN) controls 
POLISH 
COHORT 
Candidate gene case-
control study involving 20 
different athletic 
disciplines 
660 Polish athletes of national / international competitive standard 
684 Polish controls 
LITHUANIAN 
(Kaunas) 
COHORT 
Candidate gene 
association study 
involving 19 different 
athletic disciplines 
performing over 20 
groups of phenotypic 
measurements 
126 Strength-power athletes of regional / national / international 
standard including Olympic athletes 
84 Endurance athletes of regional / national / international standard 
including Olympic athletes 
197 Lithuanian controls 
LITHUANIAN 
(Vilnius) 
COHORT 
Candidate gene 
association study 
involving 15 different 
athletic disciplines 
performing 3 groups of 
phenotypic 
measurements 
59 Endurance athletes of international / regional standard 
71 Strength and speed athletes of international / regional standard 
431 Mixed team sports athletes of international / regional standard 
260 Lithuanian controls 
Table 2. Major study cohorts in genetics of elite performance (see Pitsiladis et al., 2013). 
